Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > New investor

<< Previous

Bullboard Posts

Next >>

Comment by tylerreddickon May 14, 2024 6:15pm

70 Views

Post# 36039843

RE:RE:RE:RE:New investor

biorun wrote: Abbvie and Allergan, through the global license agreement for 1067, have defacto legitimized the company and it's science platform.

Say what you want, but this holds huge street cred for the work that Stonegate will do for Sirona.

Sirona gets no "street cred" from AbbVie, as it looks like they have abandoned us, just like R&F.
If that isn't a fact. let Howie say so.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”